Xbrane Biopharma AB (XBRANE) NPV

Sell:10.00 SEKBuy:10.25 SEKPrice unchangedNo change

Prices delayed by at least 15 minutes
Sell:10.00 SEK
Buy:10.25 SEK
Change:Price unchangedNo change
Prices delayed by at least 15 minutes
Sell:10.00 SEK
Buy:10.25 SEK
Change:Price unchangedNo change
Prices delayed by at least 15 minutes

Company Information

About this company

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

Key people

Anders Tullgren
Independent Chairman of the Board
Mats Thoren
Independent Director
Martin Amark
Chief Executive Officer
Siavash Bashiri
Deputy Chief Executive Officer, Head - Biosimilars
Jane Benyami
Acting Chief Financial Officer
Bjorn Lager
Head of Quality Assurance
Anders Wallstroem
Head - Manufacturing and Supply Chain
Kristoffer Bissessar
Independent Director
Kirsti Gjellan
Independent Director
Eva Nilsagard
Independent Director
Click to see more

Key facts

  • Shares in issue
    20.61m
  • EPIC
    XBRANE
  • ISIN
    SE0026598583
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    SEK 203.58m
  • Employees
    29
  • Exchange
    Stockholm Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.